Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study)

Miyamura Koichi; Ohtake Shigeki; Ohnishi Kazunori; Usui Noriko; Nakaseko Chiaki; Fujita Hiroyuki; Fujisawa Shin; Sakura Toru; Okumura Hirokazu; Hatta Yoshihiro; Emi Nobuhiko; Naoe Tomoki

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study)

【24h】

Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study)

机译：慢性粒细胞性白血病在伊马替尼治疗的III期随机研究中，标准剂量递增与逐步剂量递增比较（JALSG CML207研究）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共5页
作者
Miyamura Koichi; Ohtake Shigeki; Ohnishi Kazunori; Usui Noriko; Nakaseko Chiaki; Fujita Hiroyuki; Fujisawa Shin; Sakura Toru; Okumura Hirokazu; Hatta Yoshihiro; Emi Nobuhiko; Naoe Tomoki;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study) [J] . Miyamura Koichi, Ohtake Shigeki, Ohnishi Kazunori, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：慢性粒细胞性白血病在伊马替尼治疗的III期随机研究中，标准剂量递增与逐步剂量递增比较（JALSG CML207研究）
2. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. [J] . Cortes JE, Baccarani M, Guilhot Journal of Clinical Oncology . 2010,第3期

机译：使用分子终点研究：酪氨酸激酶抑制剂优化和选择性研究，在新诊断，先前未治疗的慢性粒细胞白血病的慢性期患者中，每天进行400毫克甲磺酸伊马替尼与800毫克甲磺酸伊马替尼的随机，开放标签研究。
3. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: A randomized phase III trial of the Dutch-Belgian HOVON study group [J] . ThielenN., VanDerHoltB., VerhoefG.E.G., Annals of hematology . 2013,第8期

机译：大剂量伊马替尼与大剂量伊马替尼联合中剂量阿糖胞苷治疗首例慢性髓样白血病的患者：荷兰-比利时HOVON研究组的一项随机III期试验
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Phase III Randomized Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study [O] . Jorge E. Cortes, Michele Baccarani, François Guilhot, -1

机译：甲磺酸伊马替尼400毫克对800毫克的III期随机开放标签研究使用分子终点研究：在慢性期新诊断先前未经治疗的慢性粒细胞白血病患者采用分子终点：酪氨酸激酶抑制剂优化和选择性研究
7. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. [O] . Cortes JE, Baccarani M, Guilhot F, 2010

机译：每日甲磺酸伊马替尼400 mg的随机，开放标签研究与800 mg新诊断，之前未治疗的慢性粒细胞白血病患者的随机，开放性研究

Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study)

著录项

相似文献

相关主题

期刊订阅